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Abstract
Background:  Many Helicobacter pylori eradication regimens have been described. There are little
data reporting their efficacy or integration in routine clinical practice. The overall results of
eradication therapy in a cohort of patients are described and an algorithm for management
outlined.
Methods:  469 patients receiving eradication therapy in routine clinical practice were evaluated.
The successes of individual regimes as first, second and third line therapy were determined.
Results:  Overall success after one, two and three courses of therapy were 73% (95% confidence
intervals 69–77%), 94% (91–96%) and 98% (97–99%) respectively. 10 different regimens, including
many non-recommended ones were used as primary therapy. Ranitidine bismuth citrate-
amoxicillin-clarithromycin triple therapy (94.8%, 90–99%) was significantly more effective than any
other combination as primary therapy, including all proton pump inhibitor based triple therapies.
Quadruple therapy with bismuth chelate-proton pump inhibitor-tetracycline and a nitroimidazole
(70%, 52–88%) and ranitidine bismuth citrate-based triple therapy (73%, 56–90%) where more
effective second line combinations than proton pump inhibitor-triple therapies (37.5%, 12–58%).
Third line therapy directed by the results of sensitivity testing improved eradication compared to
further empirical antibiotics. The use of a proton pump inhibitor with clarithromycin and a
nitroimidazole as initial therapy was associated with a significantly worse overall eradication rate
than other combinations.
Conclusions:   Helicobacter pylori eradication rates can be maximised by using ranitidine bismuth
citrate-clarithromycin-amoxicillin containing triple therapy, followed by bismuth and nitroimidazle
containing second-line therapy, with third line combinations directed by sensitivity testing. Proton
pump inhibitor-clarithromycin-metronidazole combinations should be avoided.
Background
Treatment of gastric H. pylori infection with combina-
tions of antimicrobials is recognised as the treatment of
choice for those patients carrying the infection with pep-
tic ulcer disease and gastric MALT-lymphoma [1–3]. An-
timicrobial therapy is usually recommended following
potentially curative resection of gastric cancer and in the
presence of dysplasia [1]. The place of H. pylori eradica-
tion therapy in the management of patients with dyspep-
tic symptoms without ulceration is the subject of much
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prescribed for this group [4–8].
Randomised clinical trials have demonstrated that 7-day
proton pump inhibitor (PPI)-based triple therapies are
the usual treatment of choice for H. pylori infection
[9,10]. More recently ranitidine bismuth citrate (RBC)
and two antibiotics has been demonstrated to be an effi-
cacious first-line therapy [11–14]. Even with currently
optimal treatments there is a small but significant failure
rate (10–25%) and it has been emphasized that H. pylori
treatment strategies need to be planned to optimise the
overall eradication rates, rather than concentrating on
the results of a single treatment [15]. To this end it will be
necessary for repeated courses of therapy in order for
eradication rates to approach 100% once a decision to
treat has been made.
Despite the publication of many reports of successful
eradication regimes, there is relatively little data report-
ing the overall results in patients requiring repeated
courses of therapy, particularly during the course of rou-
tine clinical care.
Therefore the efficacy of H. pylori eradication in a cohort
of patients having routine hospital in- or outpatient care
has been studied. The primary aims of the study were to
describe the use and effectiveness of the regimens pre-
scribed by all clinicians dealing with H. pylori infection
and to report the influence of each of those regimens on
overall success. From this data it has been possible to
construct an overall strategy to maximise H. pylori.
Methods
Patients
All adult patients with a confirmed diagnosis of H. pylori
infection who received at a first course eradication ther-
apy as part of their standard in- or outpatient clinical
care at the James Paget Hospital and completed an ap-
propriate follow up between February 2000 and May
2001 were included. Patients who had received any erad-
ication therapy prior to February 2000 were excluded
from the analysis.
Patients were identified from discharge coding, endosco-
py unit database, histopathology and microbiology data-
bases and pharmacy records. Follow up 13C-urea breath
testing (Pylobactell®, BSIA, Middlesex, UK)[16] was
performed if an appropriate post-eradication assess-
ment had not been performed up to that point.
Diagnosis of H. pylori infection
Prior to the initial course of eradication therapy H. pylori
infection was diagnosed by either biopsy based rapid
urease test (CLOtest®) or histology with imunostaining
from the gastric antrum. Patients were regarded as in-
fected if either test was positive. If endoscopy was not in-
dicated on standard clinical grounds, patients with
positive H. pylori serology had a confirmatory 13C-urea
breath test before antibiotic therapy. Follow up was by
13C-urea breath test at least 4 weeks after cessation of
therapy. In those patients undergoing endoscopic follow
up after eradication therapy, biopsies were taken for cul-
ture and sensitivities (one biopsy from antrum and cor-
pus) and histology with immunostaining (two each from
antrum and body). Culture was performed in under
microaerophilic conditions at 37°C and clarithromycin
and metronidazole sensitivities assessed by E-test. Met-
ronidazole resistance was defined as MIC > 8 mg/l and
clarithromycin resistance as > 2 mg/l. Patients were re-
garded, as H. pylori negative if all biopsy-based tests at
follow up were negative. A 13C-urea breath test was per-
formed if biopsy sampling was inadequate and was re-
garded as the gold standard for the presence of H.
pylori[16].
Treatment regimens
All patients who had H. pylori eradication during the pe-
riod were included. Patients could have been under the
care of any of the specialities prescribing eradication.
The relevant specialities were two medical gastroenterol-
ogy teams (each headed by an attending (consultant),
one with a special interest in H. pylori infection), general
surgery (5 teams) or internal medicine (7 teams). Each
clinical team had freedom to prescribe any eradication
regime. At the time of the study, the district-wide guide-
lines indicated the favoured eradication regime was a 7
day course of proton pump inhibitor combined with two
of the following antibiotics: amoxicillin (A), metronida-
zole, clarithromycin (C). These are consistent with Brit-
ish Society of Gastroenterology guidelines [17]. Some
patients were referred back to their primary care physi-
cian, who then decided the exact choice of therapy. Sub-
sequent treatment after initial failures was again at the
choice of the responsible clinician. However, an in-
creased proportion of the patients requiring second line
(57%) and all those requiring third line were referred to
the care of the gastroenterologist (the author) with a spe-
cial interest in H. pylori. In general, second line therapy
was chosen empirically, using whichever of clarithromy-
cin or metronidazole was not used initially. All patients
requiring third line therapy underwent endoscopy,
choice of therapy being guided by sensitivities. No at-
tempt was made to differentiate the effects of different
proton pump inhibitors (regimens containing omepra-
zole, lansoprazole and rabeprazole were all used in twice
daily dosage) or nitroimidazoles (N)(metronidazole and
tinidazole in either twice or three times daily
dose)[13,14]. Clarithromycin and erythromycin (E) were
analysed independently.
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ication therapy after an initial failure. Several factors
contributed to this, choice of patient or clinician not to
repeat therapy in cases of non-ulcer dyspepsia, patient
lost to follow up.
Statistics
Differences between eradication rates were assessed by
Chi Square with correction for multiple comparisons.
Results are expressed as eradication rates or odds ratios
with 95% confidence intervals.
Results
First line therapy
Four hundred and ninety patients received eradication
during the period of the study, 469 were evaluable. The
remaining 31 were lost from follow up or had inadequate
data available. The indications for anti-H. pylori therapy
were: duodenal ulcer 151 (32%), gastric ulcer 107(23%),
non-ulcer dyspepsia or not endoscoped 203 (43%), pre-
vious gastric surgery 5 (1%), mild dysplasia 3 (1%). Of the
original courses of therapy: 249 (53%) were prescribed
by either of the gastroenterologists, 68 (14%) by internal
medicine specialists, 103 (22%) by general surgeons and
Table 1: Results of first line H. pylori eradication therapy.
Regimen Number treated Number successful Percent Success 95 % CI
7 days
PPI 110 71 64.5% 55.6–73.4
amoxicillin 1 g bid
nitroimidazole
7 days
PPI 175 126 72% 65.4–78.6
amoxicillin 1 g bid
clarithromycin 500 mg bid
7 days
PPI 70 46 65.7% 54.6–76.8
nitroimidazole
clarithromycin 500 mg bid
7 days
RBC 400 mg bid 97 92 94.8% 90.4–99.2*
amoxicillin 1 g bid
clarithromycin 500 mg bid
7 days
RBC 400 mg bid 5 5 100% -
Nitroimidazole
Clarithromycin 500 mg bid
14 days
RBC 400 mg bid 3 3 100% -
amoxicillin 1 g bid
7 days
PPI 2 0 0% -
amoxicillin 1 g bid
clarithromycin 500 mg bid
nitroimidazole
7 days
PPI 2 0 0% -
erythromycin 1 g bid
amoxicillin 1 g bid
7 days
erythromycin 1 g bid 4 0 0% -
nitroimidazole
7 days
tetracycline 500 mg qid 1 0 0% -
nitroimidazole
*RBC-A-C was significantly more effective than PPI-A-N, PPI-C-N, PPI-A-C (all P < 0.01).
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ent regimes were prescribed (see table 1). A 7 day PPI
plus two antibiotic regime was used in 356 (76%) of cas-
es, ranitidine bismuth citrate-based dual or triple thera-
py in 105 (22%) and non-standard regimes in 9 (2%). The
non-standard treatments were PPI with erythromycin
and amoxicillin, PPI with erythromycin and metronida-
zole, PPI with tetracycline and metronidazole and PPI
with amoxicillin, metronidazole and clarithromycin. The
overall success rate was 343/469 (73%, 95% CI 69–77%).
The results for the individual regimes are shown in table
1. There were no significant differences in the numbers
lost to follow up in the different groups. All nonstandard
regimes were unsuccessful. There were no significant
differences in the eradication rates for the different regi-
mens when the setting (primary vs. secondary care) or
endoscopic diagnosis were considered.
Ranitidine bismuth citrate triple therapy with amoxicil-
lin and clarithromycin (RBC-A-C) was significantly (P <
0.01) more effective than all of the PPI-triple the therapy
regimens. There was no significant difference between
any of the PPI-triple therapies. RBC-clarithromycin dual
therapy for 14 days and RBC-C-N triple therapy for 7
days were used very successfully (100% success) in a
small number of patients with penicillin allergy, but the
numbers involved were too small to draw comparative
conclusions.
Second line therapy
Sixty-six patients received a second course of eradication
therapy. The choices of second line therapy, following
failed initial therapy are shown in figure 1. Six different
second line eradication regimens were used, all of 7 days
duration. The results are shown in table 2. The overall
success rate was 42/66 (63.6%, 52–75.2%). Success was
significantly greater with bismuth-based (either raniti-
dine bismuth citrate or tripotassium dicitratobismuthate
(De-Nol, bismuth chelate, DCB)) (72%, 60–84%) than
PPI-based therapies (37.5%, 12–58%)(P < 0.05). After
two courses of therapy overall 385/409 (94%, 91.3–
96.7%) of patients had been cleared of H. pylori infec-
tion. Four out of five patients initially failing RBC-A-C
triple therapy were successfully treated with PPI-bis-
muth quadruple therapy. Of the patients with failed first
line therapy with PPI-based triple therapies 12/14 (86%,
66–98%) were treated successfully with RBC-A-C triple
therapy and 15/22 (68%, 51–85%) with PPI-bismuth
quadruple therapy (difference non-significant).
Table 2: Efficacy of second line H. pylori eradication therapy.
Regimen Number treated Treatment successful Perecent success 95% CI
7 days
PPI 27 19 70% 52.8–87.2*$
nitroimidazole
tetracycline 500 mg qid
DCB 240 mg bid
7 days
PPI 7 2 28% 0–61
amoxicillin 1 g bid
nitroimidazole
7 days
PPI 1 0 0% -
clarithromycin 500 mg bid
nitroimidazole
7 days
PPI 8 4 50% 15.4–84.6
amoxicillin 1 g bid
clarithromycin 500 mg bid
7 days
RBC 400 mg bid 18 13 73% 52.4–93.6*$
amoxicillin 1 g bid
clarithromycin 500 mg bid
7 days
RBC 400 mg bid 5 4 80% 45–100
tetracycline 1 g bid
nitroimidazole
* PPI-DCB-N-T and RBC-A-C were significantly more effective than PPI-A-M as second line therapy (both P < 0.05). $ Bismuth-based (PPI-DCB-N-
T or RBC-A-C) was more effective that PPI-triple therapy (P < 0.05).
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Twenty patients underwent a third course of therapy. All
had a further gastroscopy with therapeutic regimens
chosen on the basis of clarithromycin and metronidazole
resistance. The choice of therapy was as outlined in table
3. Patients in whom the H. pylori culture failed were
treated with 14 days omeprazole 20 mg twice daily, rifab-
utin 300 mg once daily and amoxicillin 1 g twice daily
[18–20]. All patients having third line therapy received
three agents for 14 days. Overall success rate with third
line therapy was 13/20 (65%, 44–86%) and the overall
success rate of patients continuing through up to 3
rounds of therapy was 398/405 (98%, 96.8–99.2%).
Success with third line therapy was higher in those with
a metronidazole or clarithromycin sensitive isolate (5/6)
(83%) compared to those with fully resistant strains (6/
10) or unknown sensitivities (2/4).
Effect of initial choice of therapy on overall eradication 
rates
Initial regimes containing both clarithromycin and a ni-
troimidazole were associated with significantly worse re-
sults overall, with lower eradication rates after logically
chosen second line therapy and sensitivity-directed third
line therapy. After two courses of therapy 13.7% of pa-
tients initially treated with PPI-nitroimidazole-clarithro-
mycin were still infected with H. pylori compared to
those receiving initial courses of PPI-A-C (4.7%) or RBC-
A-C (1%) (both P < 0.01).
Similarly PPI-nitroimidazole-clarithromycin initial ther-
apy was significantly associated with both the subse-
quent isolation of combined clarithromycin and
metronidazole strains (OR 2.25, 1.05–15.7, P < 0.05) and
failure of third line therapy (OR 14.9, 1.01–71, P < 0.01).
Of patients who continued through 3 attempts at eradi-
cation, five of the seven failing 3 courses were initially ex-
posed to nitroimidazole-clarithromycin therapy.
Discussion
This study on a large cohort of patients in routine clinical
practice has demonstrated several important findings
relevant to the efficacy of anti-H. pylori therapy. Firstly,
despite the ready availability of recommendations and
published literature a wide variety of eradication regi-
mens were prescribed as initial therapy, these included
several ineffective and not recommended regimens. De-
spite the initial use of sub-optimal regimens, the overall
successful eradication rates in the cohort of patients un-
dergoing second and third line therapies were extremely
good at 94% and 98% respectively. This suggests that it
is possible to devise a logical algorithm to maximise
eradication rates within a population. The efficacy of
RBC-A-C initial therapy exceeded PPI-based therapies,
suggesting that this therapy should be used more widely
in clinical practice. The final important conclusion was
that although 1st line eradication rates were equivalent
for all PPI-based triple therapies, the use of an initial
PPI-C-N regimen was associated an overall decrease in
eradication rates and subsequent increased isolation of
Table 3: Choice and efficacy of third line H. pylori eradication.
Resistance pattern Regimen Number of Successfully Percent
patients treated success
(95% CI)
Met – Res 14 days
Clarith – Res omeprazole 20 mg bid 10 6 60%
rifabutin 300 mg od (30–90%)
amoxicillin 1 g bid
Met – Res 14 days
Clarith – Sens RBC 400 mg bid 5 4 80%
clarithromycin 500 mg (45–100%)
bid
tetracycline 1 g bid
Met – Sens 14 days
Clarith – Res RBC 400 mg bid 1 1 100%
tinidazole 500 mg bid -
tetracycline 1 g bid
Unknown 14 days
omeprazole 20 mg bid 4 2 50%
rifabutin 300 mg od (1–99%)
amoxicillin 1 g bid
Regimens were chosen following culture and sensitivity testing after failed 2nd line therapy.
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This suggests that this combination should be avoided
within and overall management strategy.
Following the reporting of several large clinical trials it
has been accepted that 1 week PPI-based triple therapies
are the treatment of choice for H. pylori infection [1].
Overall PPI-A-N therapy produces inferior results to
clarithromycin-based combinations and several influen-
tial guidelines and recommendations advocate initial use
of PPI-clarithromycin plus either amoxicillin or metron-
idazole [1,9]. The current British Society of Gastroenter-
ology guidelines (which are due for revision) do not
specify a preference for any of the 3 PPI-based triple
therapies [17] and several important studies reporting
the development of successful use of PPI-A-N originated
from the local area [21]. Thus this regimen is well estab-
lished in the geographical area and this probably ex-
plains the continued frequent use of this regimen.
Despite the available evidence and guidelines, a variety
of non-standard choices of therapy were made by non-
gastroenterologists. These were all ineffective and pa-
tients required further treatment. Other studies have
also demonstrated the difficulty many clinicians have in
assimilating the data and guidelines on the plethora of
eradication regimens, leading to confusion and resulting
in the use of ineffective combinations [22,23]. Therefore
to make best use of resources it is important that the dis-
semination of best current practice and continued edu-
cation of clinicians dealing with H. pylori infection
continues.
Although randomised trials can provide evidence on the
maximal effect of treatments under ideal conditions, it is
still important to consider the actual efficacy of treat-
ments in routine clinical care when planning local deliv-
ery arrangements. This has been illustrated here by the
variety of regimens used by clinicians. Thus retrospec-
tive studies can compliment randomised trials. In every-
day practice, factors other than actual treatment regimen
may affect efficacy, such as counselling regarding com-
pliance, availability and accuracy of advice and clinician
interest in the problem. These factors are removed in a
formal randomised trial but may have had an effect in
the retrospective review. It was not possible to assess the
effect of seniority or speciality of clinician prescribing
therapy on eradication because of the many doctors in
training associated with each team, rendering it impossi-
ble be certain who specifically provided advice to the pa-
tient and final choice of eradication therapy. Analysis of
those regimens prescribed by multiple teams, did not
show any significant effect of team speciality on eradica-
tion rates. RBC-containing regimens were only used by
the gastroenterologist with a specific interest in H. py-
lori; this may have contributed to the excellent results by
improving compliance. It is worthwhile noting that re-
sults for PPI-A-C from this team were not superior to
other teams.
Recent studies have confirmed that ranitidine bismuth
citrate combined with clarithromycin and either a ni-
troimidazole or amoxicillin is an effective first line ther-
apy for H. pylori. Results are not generally different from
the corresponding PPI-based therapy in clinical trials
and although not widely used, some authors have sug-
gested that RBC-triple therapy should also be regarded
as a first line therapy of choice [13–15]. In the current
study RBC-AC was the most efficacious first line therapy,
the reason for the apparent superiority compared PPI-
triple therapies is not clear. No attempt to assess compli-
ance was made and clinical trials suggest little difference
in compliance between RBC- and PPI- based therapies
[13,14]. However in everyday clinical practice, as op-
posed to a closely monitored trial overall compliance
may be lower, although the enthusiasm of the relevant
clinician may have a role as discussed above.
There appears to be synergism between RBC and antibi-
otics and this enhanced antibacterial effect may offset
any loss of effect induced by failure to complete the anti-
biotic course [24]. RBC-containing regimens may also
overcome bacterial resistance to metronidazole or clari-
thromycin but in this predominantly rural Caucasian
population primary antibiotic resistance is unlikely to be
substantial and this is unlikely to explain the improved
results of RBC-A-C [25].
Even in the best clinical studies 15–25% of patients will
fail to clear H. pylori with one course of appropriate
therapy. The challenge therefore is to design an overall
Figure 1
Choice of second line therapies after first line fail-
ures. Lines indicate number of patients receiving each regi-
men after initial failures. Abbreviations used in figure: PPI-
proton pump inhibitor, A-amoxicillin, C-clarithromycin, N-
nitroimidazole, RBC-ranitidine bismuth citrate, DTB-tripos-
tassium dicitratobismuthate, T-tetracycline, e-erythromycin
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and minimised costs and the number of courses of anti-
biotics [15]. Within such a strategy it is not certain how
the different combinations of therapy and endoscopy
and culture need to be utilised. The data presented here
suggest that it is possible to plan a overall strategy with 2
courses of empirical but logically chosen antibiotics, re-
serving sensitivity testing only when a third line is con-
templated.
The importance of sensible choice of antibiotic combina-
tions is illustrated by the overall poor results in patients
initially receiving PPI-C-N triple therapy. Although the
results of this group were comparable to the other PPI-
triple therapies as initial therapy, the final eradication
rate after repeated courses was significantly lower in this
group. This failure seemed to be due to the emergence of
multiply resistant strains as evidenced by the results of
culture testing after the second failed course. Clarithro-
mycin and metronidazole are the most potent antibiotics
against H. pylori. Although combination therapies with
both of these agents are efficacious, as demonstrated
here, there is no logical choice of second line therapy in
those patients in whom eradication fails. Failure of clar-
ithromycin or nitroimidazole containing regimens is of-
ten associated with the emergence of secondary
antibiotic resistance and this would be consistent with
the data presented here [26]. The treatments of multi-re-
sistant H. pylori remains problematical, several regi-
mens have been used but there is not consensus as to the
choice of treatment [25]. Therefore, as suggested previ-
ously [15], steps should be taken to minimise the prob-
lems of secondary resistance and to this end, it is
suggested that PPI-C-N regimes are not used as initial
empirical therapy.
There are relatively few data reporting the efficacy of sec-
ond line therapy, and further large randomised and cost-
efficacy studies awaited. In the current study empirical
second line therapy was effective when chosen logically.
From this it can be concluded that the second regime
should use whichever of clarithromycin or nitroimida-
zole was not used initially. Overall, bismuth-containing
(whether RBC or bismuth chlelate) therapies were more
effective as second line treatments than PPI-based triple
therapies without bismuth. This is in agreement with a
recent report highlighting the better results with second
line bismuth-based therapy [27]. Quadruple bismuth-
containing therapy performs well even in metronidazole-
resistant cases and in a small study was effective for
RBC-triple therapy failures [28,29]. The complexity and
number of tablets inherent in quadruple therapy suggest
it is most suited to a rescue role rather than initial thera-
py.
For first line clarithromycin failures, 1 week quadruple
therapy with a PPI, bismuth chelate, tetracycline and a
nitroimidazole seems the logical choice. Seven-day ther-
apy with RBC-tetracycline and a nitroimidazole was ef-
fective in the small number of patients and may become
the treatment of choice in future if further studies con-
tinue to be supportive [11,30]. In one comparison of "sal-
vage" regimes, RBC-N-T produced superior eradication
rates than quadruple therapy (83 vs 57%) [30]. If the in-
itial failed regimen contained a nitroimidazole; a clari-
thromycin and amoxicillin-containing regimen (either
RBC-A-C, or PPI-A-C) would be the logical choice. The
current study suggests RBC-A-C is the logical choice in
this situation as it produced significantly better second
line eradication than the PPI-based therapy. Future
studies reporting head to head comparisons of RBC and
bismuth chelate-based second line therapies will be use-
ful in guiding future therapy.
Having used both clarithromycin and nitroimidazole-
containing regimens, there is no logical effective choice
for 3rd line therapy, although only about 6% of patients
will reach this point. Therefore if H. pylori eradication is
desired in such patients, endoscopy, culture and sensi-
tivity-directed therapy seem appropriate. In the current
study 3rd line eradication was more effective in those
with sensitivity-directed therapy than either empirical
"blind" therapy in culture failures or multi-resistant
strains. Further studies with novel regimens in multi-re-
sistant strains are awaited. The combination of PPI-
amoxicillin and rifabutin was used for 3rd line patients
with multi-resistant or unknown resistance pattern
strains. This regimen shows some promise as final sal-
vage therapy; success rates in the region of 60–85% have
been reported. This success rate of this combination may
be independent of clarithromycin and metronidazole
sensitivities [18–20]. In the current study the success
rate of RBC-based sensitivity-directed therapy was supe-
rior to PPI-A-rifabutin triple therapy; this suggests that
endoscopy and sensitivity testing at this point is worth-
while rather than more widespread use of PPI-A-rifabu-
tin.
The choice of therapy in penicillin-sensitive patients re-
mains problematical. As outlined previously PPI-C-N
combinations should probably be avoided because of the
adverse effects on overall eradication rates. RBC-C-N
would be an alternative; in randomised trials this combi-
nation achieved higher eradication rates than other tri-
ple therapies but approximately 15% of courses were still
ineffective [13,14], thus the risk of treatment failure
would be minimised. However there is still no rational
choice of second line therapy after RBC-C-N and further
reports of the overall efficacy of this regimen after second
line salvage are needed. A 14-day combination of RBC
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tive patients: eradication rates of 71–86 % have been re-
ported [11,31,32] and this regimen has the advantage of
logically being followed, if needed, by PPI-bismuth-ni-
troimidazole-tetracycline quadruple therapy.
Conclusions
This study on the overall efficacy of H. pylori eradication
has demonstrated that greater education of clinicians re-
garding choice of suitable regimens is needed. The data
show that rates of eradication within a population can be
maximised by logical choice of therapies. Initial therapy
with PPI-C-N was associated with an increased risk of
failure to clear the infection. It is suggested that first line
therapy with a clarithromycin-amoxicillin containing tri-
ple therapy is followed by a bismuth-nitroimidazole-
based second regimen. In view of the small numbers of
patients failing this second line therapy, endoscopy and
sensitivity testing can be reserved for third line therapy
(see figure 2). It is recommended that those prescribing
H. pylori eradication therapies continually assess their
success rate and adjust the relevant local practices and
policies in line with the results and local bacterial resist-
ance patterns. More research is required on the integrat-
ed use of the different combination therapies; these
studies need to consider overall efficacy as well as cost ef-
fectiveness when comparing different regimes and dif-
ferent antibiotic doses. Detailed studies of second and
third line therapies are particularly needed.
Abbreviations used in this paper
PPI-proton pump inhibitor, A-amoxicillin, C-clarithro-
mycin, N-nitroimidazole, RBC-ranitidine bismuth cit-
rate, DCB-tripostassium dicitratobismuthate, T-
tetracycline, E-erythromycin, od once daily, bid twice
daily, tid three times daily, qid four times daily
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